Soluble fibrin monomer degradation products as a potentially useful marker for hypercoagulable states with accelerated fibrinolysis

Clinica Chimica Acta

Volumn 386, Issue 1-2, 2007, Pages 38-45

  Ieko, Masahiro ^a   Nakabayashi, Toru ^a   Tarumi, Takashi ^a   Naito, Sumiyoshi ^a   Yoshida, Mika ^a   Kanazawa, Kaori ^a   Mizukami, Kazuhiro ^a   Koike, Takao ^b  

^a HEALTH SCIENCES UNIVERSITY OF HOKKAIDO   (Japan)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Disseminated intravascular coagulation; Fibrin monomer degradation products; Fibrinolysis; Hypercoagulable state; Soluble fibrin monomer

Indexed keywords

EDETIC ACID; FIBRIN DEGRADATION PRODUCT; FIBRIN MONOMER; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; BINDING AFFINITY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DEGRADATION; DISSEMINATED INTRAVASCULAR CLOTTING; FIBRINOLYSIS; HUMAN; HYPERCOAGULABILITY; IMMUNOASSAY; MAJOR CLINICAL STUDY; PLASMA; PRIORITY JOURNAL; THROMBOGENICITY; THROMBOSIS; WESTERN BLOTTING;

ADULT; AGED; ANTIBODIES, MONOCLONAL; BIOLOGICAL MARKERS; BLOOD COAGULATION DISORDERS; CASE-CONTROL STUDIES; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOLYSIS; HUMANS; MALE; MIDDLE AGED; SOLUBILITY; THROMBOSIS; TIME FACTORS;

EID: 34548702660     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2007.07.023     Document Type: Article

References (33)

1. Budzynski A.Z., Olexa S.A., and Pandya B.V. Fibrinogen polymerization site in fibrinogen and fibrin fragment. Ann NY Acad Sci 408 (1983) 301-314
2. Blombäck B., Hessel B., Hogg D., and Thelkildsen L. A two-step fibrinogen-fibrin transition in blood coagulation. Nature 275 (1978) 501-505
3. Doolittle R.F., Bouma III B.A., Strong D., and Watt K.W.K. The covalent structure of human fibrinogen. In: Bing D.H. (Ed). The Chemistry and Physiology of the Human Plasma Proteins (1989), Pergamon Press, New York 77-95
4. Shainoff J.R., and Page I.H. Significance of criopro-fibrin in fibrinogen-fibrin conversion. J Exp Med 116 (1962) 687-707
5. Brass E.P., Forman W.B., Edwards R.V., and Lindan O. Fibrin formation: the role of the fibrinogen-fibrin complexes. Thromb Haemost 36 (1979) 37-48
6. Greff H., von Hugo R., and Hafter R. On soluble fibrinogen-fibrin complexes. Thromb Res 16 (1979) 575-576
7. Folk J.E., and Finayson J.S. The ε-(γ-glutamyl)lysine crosslink and the catalytic role of transglutaminases. Adv Protein Chem 31 (1977) 1-133
8. Shainoff J.R., and DiBello P.M. The circulatory half-lives of α-profibrin and α-fibrin monomer, and comparisons with other fibrin(ogen) derivatives. Thromb Haemost 89 (2003) 48-52
9. Nossel H.L., Yudelman I., Canfield R.E., et al. Measurement of fibrinopeptide A in human blood. J Clin Invest 54 (1974) 43-53
10. Siegal T., Seligsohn V., Aghai E., and Modan M. Clinical and laboratory aspects of disseminated intravascular coagulation (DIC). Thromb Haemost (1978) 122-134
11. Okajima K., Uchiba M., Murakami K., Okabe H., and Takatsuki K. Determination of plasma soluble fibrin using a new ELISA method in patients with disseminated intravascular coagulation. Am J Hematol 51 (1996) 186-191
12. Wada H., Wakita T., Nakase T., et al. Increased plasma-soluble fibrin monomer concentrations in patients with disseminated intravascular coagulation. Am J Hematol 51 (1996) 255-260
13. Soe G., Kohno I., Inuzuka K., Itoh Y., and Matsuda M. A monoclonal antibody that recognizes a neo-antigen exposed in the E domain of fibrin monomer complexed with fibrinogen or its derivatives: its application to the measurement of soluble fibrin in plasma. Blood 88 (1996) 2109-2117
14. Hanano A., Tanaka S., Takeda Y., Umeda M., and Sakata Y. A novel monoclonal antibody to fibrin monomer and soluble fibrin for the detection of soluble fibrin in plasma. Clin Chim Acta 318 (2002) 25-32
15. Kubo T., Kitajima I., Makinodan A., et al. Fibrin monomer could be a useful predictor of pulmonary embolism after total hip arthroplasty: preliminary report. J Orthop Sci 6 (2001) 119-122
16. Nakahara K., Kazahaya Y., Shintani Y., et al. Measurement of soluble fibrin monomer-fibrinogen complex in plasmas derived from patients with various underlying clinical situations. Thromb Haemost 89 (2003) 832-836
17. Dempfle C.-E., Kaden J.J., Haase K.K., and Borggrefe M. Course of indicators of thrombin activity in the early phase of acute myocardial infarction: effect of fibrinolytic therapy and acute precutaneous coronary angioplasty. Thromb Haemost 90 (2003) 147-154
18. Kobayashi N., Maegawa K., Takada M., Tanaka H., and Gonmori H. Criteria for diagnosis of DIC based on the analysis of clinical and laboratory finding in 345 DIC patients collected by the Research Committee on DIC in Japan. Bibl Haematol 49 (1987) 265-275
19. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227 (1970) 680-685
20. Bredbacka S., Blombäck M., Wiman B., and Pelzer H. Laboratory methods for detecting disseminated intravascular coagulation (DIC): new aspects. Acta Anaesthesiol Scand 37 (1993) 125-130
21. Wada H., Sakuragawa N., Mori Y., et al. Hemostatic molecular markers before the onset of disseminated intravascular coagulation. Am J Hematol 60 (1999) 273-278
22. Ginsberg J.S., Siragusa S., Douketis J., et al. Evaluation of a soluble fibrin assay in patients with suspected deep vein thrombosis. Thromb Haemost 74 (1995) 833-836
23. Bredbacka S., Blombäck M., and Wiman B. Soluble fibrin: a predictor for the development and outcome of multiple organ failure. Am J Hematol 46 (1994) 289-294
24. MacCarron B.I., Marder V.J., and Francis C.W. Reactivity of soluble fibrin assays with plasmic degradation products of fibrin and in patients receiving fibrinolytic therapy. Thromb Haemost 82 (1999) 1722-1729
25. Dempfle C.-E., Zips S., Ergül H., Heene D.L., and FACT study group. The fibrin assay comparison trial (FACT): correlation of soluble fibrin assays with D-dimer. Thromb Haemost 86 (2001) 1204-1209
26. Selim T.E., Ghoneim H.R., Khashaba M.T., and Rakha S.A. Plasma soluble fibrin monomer complex is a useful predictor of disseminated intravascular coagulation in neonatal sepsis. Haematologica 90 (2005) 419-421
27. Elias A., Cazanave G., Nguyen F., Elias M., Bongard V., and Cambus J.-P. Comparison of the diagnostic performance of three soluble fibrin monomer tests and a D-dimer assay in patients with clinically suspected deep vein thrombosis of the lower limbs. Haematologica 89 (2004) 499-501
28. Wada H., Wakita Y., Nakase T., et al. Outcome of disseminated intravascular coagulation in relation to the score when treatment was begun. Mie DIC Study Group. Thromb Haemost 74 (1995) 848-852
29. Yudelman I., Nossel H.L., Kaplan K.L., Hirsh J., and Greenberg J. Plasma fibrinopeptide A concentrations in symptomatic thromboembolism. Blood 51 (1978) 1189-1195
30. Rosenberg R.D., and Damus P.S. The purification and mechanism of action of human antithrombin-heparin cofactor. J Biol Chem 248 (1973) 6490-6505
31. Becker D.M., Philbrick J.T., Bachhuber T.L., and Humphries J.E. D-dimer testing and acute venous thromboembolism. A shortcut to accurate diagnosis?. Arch Intern Med 156 (1996) 939-946
32. Mak K.H., Lee L.H., Wong A., et al. Thrombin generation and fibrinolytic activities among patients receiving reduced-dose alteplase plus abciximab or undergoing direct angioplasty plus abciximab for acute myocardial infarction. Am J Cardiol 89 (2002) 930-936
33. Fassbender K., Dempfle C.-E., Mielke O., et al. Changes in coagulation and fibrinolysis markers in acute ischemic stroke treated with recombinant tissue plasminogen activator. Stroke 30 (1999) 2101-2104